Centessa discontinues SerpinPC, launches ORX750 Phase 2a, Q3 net loss $42.6M

Centessa Pharmaceuticals plc

Additional interim Phase 1 data for ORX750 in sleep-deprived volunteers showed statistically significant increase in wakefulness at all doses with favorable safety; Phase 2a initiated in NT1, NT2, IH.
Discontinued SerpinPC development after interim analysis; net savings of ~$200M reallocated to OX2R agonist franchise.
Cash $518.4M as of Sept 30, 2024; expected to fund operations into mid-2027.
Completed upsized public offering in Sept 2024 resulting in net proceeds of ~$242.7M.
Advancing ORX142 and ORX489 in IND-enabling studies; clinical data expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.